FDA clears path for Phase 3 testing following positive Type B meetingRegulatory alignment confirms preclinical data sufficient for pivotal initiationPhase 3 to include two 28-day trials and a 12-month safety extensionCPL’36 demonstrated strong efficacy and safety in prior Phase 2 studyProgram expansion planned into additional CNS indications, including Parkinson’s disease WARSAW, Poland, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Celon Pharma S.A. (WSE: CLN) announced today it has secured a key regulatory milestone ...

DELTA, British Columbia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”) (TSX.V:AMY | OTCQB:AMYZF | FSE:ID4), a critical mineral refining and lithium-ion battery upcycling company, is pleased to announce that it has contracted Rain City Industrial to lead the design and construction of the Company’s new laboratory facility at its recently acquired headquarters and operations center in Delta, B.C. The new lab will expand RecycLiCo’s capacity to advance its c ...

TransUnion’s latest study reveals 200 Canadian business leaders surveyed said their companies lost an estimated CAD$111 billion to fraud in the past year, with synthetic identity scams now accounting for over a quarter of those losses. More than a tenth of both online communities and gambling transactions coming from Canada were suspected of digital fraud in the first half (H1)1 of 2025 – with online communities experiencing a 68% year-over-year (YoY) increase in the volume of attempts. Key Study Findings: ...

Key Points Immuron submits Investigational new drug (IND) application to FDA for clinical development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI)Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 MELBOURNE, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is pleased to announce that it has submitted an Investigational New Drug (IND) application to the United States Food and D ...

One Job? In This Economy? Fiverr's Next Gen of Work research finds 54% of Gen Z and Gen Alpha believe traditional employment will become obsolete, with 42% embracing a '9-whenever' mindset Fiverr's Next Gen of Work Report Fiverr's Next Gen of Work Report NEW YORK, Oct. 08, 2025 (GLOBE NEWSWIRE) -- A weakening job market and a fundamental shift in entry-level hiring are driving Gen Z to reject traditional career paths and turn toward multiple streams of income — known as “income stacking” — to ensure fina ...

CALGARY, Alberta, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) today announced that it has entered into an amending agreement in respect of the arrangement agreement dated August 21, 2025 (as amended, the “Amended Agreement”) to acquire MEG Energy Corp. (TSX: MEG) (“MEG”). Under the terms of the Amended Agreement, each MEG shareholder will have the option to elect to receive, for each MEG common share, (i) $29.50 in cash; or (ii) 1.240 Cenovus common shares, subject to roundi ...

VANCOUVER, British Columbia, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) reports production results for the third quarter of 2025 from its three operating mines located in West Africa and Latin America. Q3 2025 highlights Gold equivalent production of 72,462 ounces4 compared to 73,123 gold equivalent ounces (GEO) in Q3 20241,2 and 71,229 GEO in Q2 20251,3Consolidated GEO production for the first nine months of 2025, including the Yaramoko Mine, totaled 251,871 ounces Fortun ...

- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis (MS) -  - Pivotal Phase 3 clinical trial evaluating orelabrutinib in patients with Primary Progressive MS (PPMS) initiated; Pivotal Phase 3 clinical trial in patients with Secondary Progressive MS (SPMS) expected to initiate in 1Q 2026 - - A novel oral IL-17AA/AF inhibitor, and an oral, brain-penetr ...

MANCHESTER, United Kingdom and HYDERABAD, India, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC Partnership designed to provide innovator biopharma companies with end-to-end Chemistry, Manufacturing and Controls (CMC) services. The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and ...

Vascular case with Zenition October 8, 2025 Global adoption milestone underscores innovation in mobile C-arm surgical and interventional imaging, with more than 15 million patients treated in 170+ countries every year Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the 5,000th installation of its Philips Zenition mobile surgery imaging system at Kolín Regional Hospital in the Czech Republic. Since its launch in 2019, Zenition has ...